The addition of clofarabine to standard induction therapy for newly diagnosed acute myeloblastic leukemia reduced the probably of relapse but increased toxicity and had no effect on survival.

Source: CancerNetworkCategory: Cancer & Oncology Authors: Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news

Related Links:

Publication date: Available online 11 August 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Jianai Sun, Jingjing Zhu, De Zhou, Lixia Zhu, Xiudi Yang, Mixue Xie, Li Li, Xianbo Huang, Mingyu Zhu, Yanlong Zheng, Wanzhuo Xie, Xiujin YeAbstractIn this retrospective data analysis of 288 newly diagnosed adult acute promyelocytic leukemia patients in Hangzhou, China, we report an early death rate of 5.9% (17/288 patients). The median follow-up time was 32 months (6–78 months), and the 3-year disease-free survival (DFS) and overall survival (OS) rates were 90.83% and 91.69%, respectively. In the multivariable an…

ConclusionOur study confirms the high prevalence of AML in elderly patients with generally poor outcomes. Selected patients with a good performance status and those who received intensive induction treatment could have a long-term survival.

UCLA Health has joined an important national clinical trial that uses genetic testing to match people who have acute myeloid leukemia, or AML, with new therapies. UCLA ’s hospital system is the first in California to offer people the opportunity to participate.The Beat AML Master Trial will evaluate a precision-based medicine approach to treating the disease; it will allow people with the disease to have immediate access to new treatments that are currently in development without having to try more traditional approaches first. The approach could streamline a patient ’s course of treatment and, ultimately, save…

Elderly patients with acute myeloid leukemia (AML) have a poorer prognosis than younger ones. Several factors contribute to the poor outcomes for this patient group.

Source: Clinical Lymphoma, Myeloma and LeukemiaCategory: Hematology Authors: Tags: Original Study Source Type: research

ConclusionsOur data indicate that the cytotoxic activity of P1 and P2 on leukemia/lymphoma cells is mediated by proteasome inhibition, leading to activation of pro-apoptotic pathways.

Source: Cellular OncologyCategory: Cancer & Oncology Source Type: research

Selective destruction of senescent cells in old tissues offers the promise of some degree of rejuvenation, coupled with effective therapies for a range of age-related diseases that currently cannot be controlled. In the past few years, a number of companies have raised venture funding for the development of senolytic therapies, those capable of removing some portion of senescent cells with an acceptable side-effect profile. The potential market is enormous, and thus despite the many potential competitors, any new mechanism by which senescent cells can be destroyed might be the pathway to success and revenue for the individ…

Source: Fight Aging!Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs

This study shows that CRL4DCAF2 is crucial for controlling NIK stability and highlights a unique mechanism that controls inflammatory diseases.

Source: The Journal of Experimental MedicineCategory: Internal Medicine Authors: Tags: Autoimmunity, Innate Immunity and Inflammation Articles Source Type: research

Curry J, Featherston S, Foglesong J, Shoberu B, Gulbis A, Mireles ME, Hafemeister L, Nguyen C, Kapoor N, Rezvani K, Neelapu SS, Shpall EJ, Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network
In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children and young adults with relapsed and/or refractory CD19+ acute lymphoblastic leukaemia became the first gene therapy to be approved in the USA. This innovative form of cellular immunotherapy has been associated with remarkable response rates but is also associated with unique and often severe toxicities, which …

Source: Clinical Lymphoma and MyelomaCategory: Cancer & Oncology Authors: Tags: Nat Rev Clin Oncol Source Type: research

Publication date: Available online 4 August 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kiyomi Mashima, Iekuni Oh, Takashi Ikeda, Yumiko Toda, Shoko Ito, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Kaoru Morita, Ryoko Yamasaki, Yasufumi Kawasaki, Miyuki Sugimoto, Chihiro Yamamoto, Masahiro Ashizawa, Shin-Ichiro Fujiwara, Kaoru Hatano, Kazuya Sato, Ken Omine, Kazuo Muroi, Yoshinobu KandaAbstractBackgroundWT1 mRNA expression is a universal marker of MRD in patients with acute myeloid leukemia (AML). The aim of this retrospective study was to evaluate the ability of serial measurement of peripheral blood …

Publication date: Available online 13 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Marielle Perry, Sarah Bertoli, Clément Rocher, Sandrine Hayette, Sophie Ducastelle, Fiorenza Barraco, Hélène Labussière-Wallet, Gilles Salles, Christian Recher, Xavier Thomas, Etienne PaubelleAbstractBackgroundOutcome of patients with mutation of the FLT3 tyrosine kinase domain (FLT3-TKD) in acute myeloid leukemia (AML) remains controversial.Patients and MethodsHerein, we present a retrospective study of 126 newly diagnosed patients with AML performed in 2 French centers.ResultsFLT3-TKD mutati…

Source link


Please enter your comment!
Please enter your name here